Palliative radiotherapy is effective for both well‐ and poorly differentiated neuroendocrine neoplasms
Journal of Medical Imaging and Radiation Oncology · 2024
DOI: 10.1111/1754-9485.13597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2024. Verfasst von Eileen O'Reilly und 5 weiteren Autor:innen. Beteiligte Einrichtung: Radiation Oncology, Te Whatu Ora - Health New Zealand Waitaha Canterbury, Christchurch, New Zealand. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Small Cell Lung Carcinoma, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Introduction
The outcomes of palliative radiation therapy (RT) for neuroendocrine neoplasms (NEN) are seldom reported. We investigated outcomes following palliative radiotherapy in a cohort of patients with NENs. We hypothesised that well‐differentiated NEN will be less likely to have a clinical response than poorly differentiated NEN.
Methods
Patients who received at least one course of palliative RT were identified using the New Zealand NETwork! Registry. Patients with Merkel cell carcinoma, pulmonary small cell carcinoma or asymptomatic patients were excluded. Clinical response to RT within 90 days and overall survival were analysed alongside clinical variables (fractionation, RT site, tumour differentiation and tumour primary site).
Results
The cohort comprised 79 patients, with 147 courses of palliative RT delivered. Clinical response was measurable for 100 courses, with clinical response rate of 76%. A course delivered to a well‐differentiated NEN was associated with 2.02‐fold (95% CI 0.67, 6.12; P = 0.21) increase in odds of a clinical response compared to a poorly differentiated NEN. Median overall survival from the first fraction of RT was 94 days (95% CI 80, 138 days). Overall survival was higher in well‐differentiated NEN than in poorly differentiated NEN (HR 0.2, 95% CI 0.10–0.40, P ‐value < 0.001); 30‐day mortality was 7%. There were significantly reduced odds of clinical response for non‐bone sites, and for courses >10 fractions compared to a single fraction.
Conclusion
Palliative RT is an appropriate option for management of symptoms in patients with both well‐ and poorly differentiated metastatic NEN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Radiation Oncology, Te Whatu Ora - Health New Zealand Waitaha Canterbury, Christchurch, New Zealand.
- Radiation Oncology, Te Whatu Ora Te Toka Tumai Auckland, Waipapa Taumata Rau/The University of Auckland, Auckland, New Zealand.
- Cancer Trials New Zealand, Waipapa Taumata Rau/The University of Auckland, Auckland, New Zealand.
- Cancer Trials New Zealand, University of Otago, Dunedin, New Zealand.
- Department of Molecular Medicine and Pathology, Waipapa Taumata Rau/The University of Auckland, Auckland, New Zealand.
- Medical Oncology, Te Whatu Ora Te Toka Tumai Auckland, Waipapa Taumata Rau/The University of Auckland, Auckland, New Zealand.
ORCID-Profile: Eileen O'Reilly
Zitieren
APA
O'Reilly, E., Lao, L., Woodhouse, B., Sharples, K., Print, C., & Lawrence, B. (2024). Palliative radiotherapy is effective for both well‐ and poorly differentiated neuroendocrine neoplasms. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.13597
Vancouver
O'Reilly E, Lao L, Woodhouse B, Sharples K, Print C, Lawrence B. Palliative radiotherapy is effective for both well‐ and poorly differentiated neuroendocrine neoplasms. Journal of Medical Imaging and Radiation Oncology. 2024. doi:10.1111/1754-9485.13597
BibTeX
@article{OReilly2024,
author = {O'Reilly, Eileen and Lao, Louis and Woodhouse, Braden and Sharples, Katrina and Print, Cris and Lawrence, Ben},
title = {Palliative radiotherapy is effective for both well‐ and poorly differentiated neuroendocrine neoplasms},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2024},
doi = {10.1111/1754-9485.13597}
}
EUVIMED